User profiles for Peter Jüni
 | Peter JüniProfessor of Medicine and Clinical Trials, University of Oxford Verified email at ndph.ox.ac.uk Cited by 269102 |
Assessing the quality of controlled clinical trials
The quality of controlled trials is of obvious relevance to systematic reviews. If the “raw material”
is flawed then the conclusions of systematic reviews cannot be trusted. Many reviewers …
is flawed then the conclusions of systematic reviews cannot be trusted. Many reviewers …
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …
…, HV Huikuri, I Johansson, P Jüni… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …
exercising their clinical judgment, as well as in the determination and the implementation of …
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Background Whether the two drug-eluting stents approved by the US Food and Drug
Administration—a sirolimus-eluting stent and a paclitaxel-eluting stent—are associated with …
Administration—a sirolimus-eluting stent and a paclitaxel-eluting stent—are associated with …
The hazards of scoring the quality of clinical trials for meta-analysis
ContextAlthough it is widely recommended that clinical trials undergo some type of quality
review, the number and variety of quality assessment scales that exist make it unclear how to …
review, the number and variety of quality assessment scales that exist make it unclear how to …
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial
Background It is unclear whether radial compared with femoral access improves outcomes
in unselected patients with acute coronary syndromes undergoing invasive management. …
in unselected patients with acute coronary syndromes undergoing invasive management. …
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
P Jüni, L Nartey, S Reichenbach, R Sterchi, PA Dieppe… - The lancet, 2004 - thelancet.com
Background The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of
cardiovascular adverse effects. An increased risk of myocardial infarction had been observed …
cardiovascular adverse effects. An increased risk of myocardial infarction had been observed …
[HTML][HTML] Fractional flow reserve–guided PCI versus medical therapy in stable coronary disease
Background The preferred initial treatment for patients with stable coronary artery disease is
the best available medical therapy. We hypothesized that in patients with functionally …
the best available medical therapy. We hypothesized that in patients with functionally …
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Flaws in the design, conduct, analysis, and reporting of randomised trials can cause the
effect of an intervention to be underestimated or overestimated. The Cochrane Collaboration’s …
effect of an intervention to be underestimated or overestimated. The Cochrane Collaboration’s …
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Non-randomised studies of the effects of interventions are critical to many areas of healthcare
evaluation, but their results may be biased. It is therefore important to understand and …
evaluation, but their results may be biased. It is therefore important to understand and …
[HTML][HTML] Percutaneous closure of patent foramen ovale in cryptogenic embolism
Background The options for secondary prevention of cryptogenic embolism in patients with
patent foramen ovale are administration of antithrombotic medications or percutaneous …
patent foramen ovale are administration of antithrombotic medications or percutaneous …
